Skyrizi and Isoniazid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Skyrizi and Isoniazid. Common interactions include blood lactic acid increased among females and drug-induced liver injury among males.

The phase IV clinical study analyzes what interactions people who take Skyrizi and Isoniazid have. It is created by eHealthMe based on reports of 13 people who take Skyrizi and Isoniazid from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Dec, 08, 2022

13 people who take Skyrizi and Isoniazid together, and have interactions are studied.


What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 9,469 Skyrizi users for its effectiveness, alternative drugs and more.

What is Isoniazid?

Isoniazid has active ingredients of isoniazid. It is often used in tuberculosis. eHealthMe is studying from 18,145 Isoniazid users for its effectiveness, alternative drugs and more.

Number of Skyrizi and Isoniazid reports submitted per year:

Skyrizi and Isoniazid drug interactions.

Common Skyrizi and Isoniazid drug interactions by gender *:

female:

  1. Blood lactic acid increased
  2. Breast cancer metastatic
  3. Neutrophil count increased
  4. Pain
  5. Pyrexia
  6. Streptococcal sepsis
  7. Radius fracture
  8. Hepatotoxicity
  9. Peripheral swelling
  10. Rosacea

male:

  1. Drug-induced liver injury
  2. Mycobacterium tuberculosis complex test positive
  3. Death
  4. Diffuse large b-cell lymphoma

Common Skyrizi and Isoniazid drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Drug-induced liver injury

40-49:

n/a

50-59:

  1. Hepatotoxicity
  2. Peripheral swelling
  3. Rosacea
  4. Breast cancer metastatic

60+:

  1. Psoriasis
  2. Mycobacterium tuberculosis complex test positive
  3. Altered state of consciousness
  4. Blood lactic acid increased
  5. Death
  6. Diffuse large b-cell lymphoma
  7. Neutrophil count increased
  8. Pain
  9. Pyrexia
  10. Streptococcal sepsis

Common conditions people have *:

  1. Psoriasis (immune-mediated disease that affects the skin): 13 people, 100.00%
  2. Latent Tuberculosis (hidden tuberculosis): 6 people, 46.15%
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 23.08%
  4. Thyroid Diseases: 2 people, 15.38%
  5. High Blood Cholesterol: 2 people, 15.38%
  6. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 7.69%
  7. High Blood Pressure: 1 person, 7.69%
  8. Dyslipidaemia (abnormal amount of lipids): 1 person, 7.69%
  9. Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 1 person, 7.69%
  10. Diabetes: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and Isoniazid?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Skyrizi and Isoniazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Skyrizi side effects:

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Isoniazid side effects:

Browse all side effects of Isoniazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Skyrizi interactions:

Browse all interactions between Skyrizi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Isoniazid interactions:

Browse all interactions between Isoniazid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa and isoniazid (the active ingredients of Skyrizi and Isoniazid, respectively), and Skyrizi and Isoniazid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Skyrizi and Isoniazid.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: